Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: consensus proposal from the SEMNIM and SEN

Arbizu, Javier; García‐Ribas, Guillermo; Carrió, Ignasi; Garrastachu, Puy; Martínez-Lage, Pablo; Molinuevo, José Luís

doi:10.1016/j.remnie.2015.05.004

Cited by 7 publications

(11 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this naturalistic study, we have attempted to estimate the impact of amyloid-PET on the diagnostic certainty and therapeutic approach of AD, added to the routine diagnostic procedures, in a subgroup of patients in which AUC recommend the investigation of their beta-amyloid burden to assess clinical management. [11,16] The population from which patients were recruited is representative of the population of eastern and southern Spain, asking for specialized help in the study of cognitive impairment, when the initial clinical evaluation is insufficient for diagnosis.…”

Section: Discussionmentioning

confidence: 99%

“…This case series included patients from 2 level-3 hospitals (A: 1.75 × 10 6 inhabitants; B: 1.5 × 10 6 inhabitants) who fulfilled clinical AUC for PET-amyloid scan in agreement with international [11] and national [16] consensuses. According recruitment could be considered as ambispective (in center A in 12 cases and in center B in 6 cases, data were collected retrospectively; in the rest of the cases the information were collected prospectively).…”

Section: Methodsmentioning

confidence: 99%

“…Four subgroups of these patients were considered for investigation of their beta-amyloid burden to guide clinical management and according to AUC [11,16] :…”

Section: Methodsmentioning

confidence: 99%

“…[11] The AUC from AIT could be considered as restrictive, [11,15] but support the basis for the national consensus. [16] As the authors refers in its report, its suggestions proceed from a literature revision and the interpretation of the previous knowledge in precise clinical settings, but “… empirical evidence of impact on clinical outcomes is not yet available .” [11]…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria

et al. 2019

View full text Add to dashboard Cite

To evaluate the use of amyloid-positron emission tomography (PET) in routine clinical practice, in a selected population with cognitive impairment that meets appropriate use criteria (AUC). A multicenter, observational, prospective case-series study of 211patients from 2 level-3 hospitals who fulfilled clinical AUC for amyloid-PET scan in a naturalistic setting. Certainty degree was evaluated using a 5-point Likert scale: 0 (very low probability); 1 (low probability); 2 (intermediate probability); 3 (high probability); and 4 (practically sure), before and after amyloid PET. The treatment plan was considered as cognition-specific or noncognition-specific. Amyloid-PET was positive in 118 patients (55.9%) and negative in 93 patients (44.1%). Diagnostic prescan confidence according amyloid-PET results showed that in both, negative and positive-PET subgroup, the most frequent category was intermediate probability (45.7% and 55.1%, respectively). After the amyloid-PET, the diagnostic confidence showed a very different distribution, that was, in the negative-PET group the most frequent categories are very unlikely (70.7%) and unlikely (29.3%), while in the positive-PET group were very probable (57.6%) and practically sure (39%). Only in 14/211 patients (6.6%) the result of the amyloid-PET did not influence the diagnostic confidence, while in 194 patients (93.4%), the diagnostic confidence improved significantly after amyloid-PET results. The therapeutic intention was modified in 93 patients (44.1%). Specific treatment for Alzheimer disease was started, before amyloid-PET, in 80 patients (37.9%). This naturalistic study provides evidence that the implementation of amyloid-PET is associated with a significant improvement in diagnostic confidence and has a high impact on the therapeutic management of patients with mild cognitive impairment fulfilled clinical AUC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…Four subgroups of these patients were considered for investigation of their beta-amyloid burden to guide clinical management and according to AUC [11,16] :…”

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Cerebrospinal fluid (CSF) core biomarkers such as β-amyloid 42 (βA42) peptide and total/phosphorylated tau protein levels correlate well with AD brain changes [2,3]. Likewise, neuroimaging biomarkers such as positron emission tomography (PET) scans with tracers that bind to β-amyloid or tau protein are also promising tools for detecting AD [4]. Nevertheless, there are still several roadblocks CONTACT Maite Mendioroz maitemendilab@gmail.com NeuroEpigenetics Laboratory (Navarrabiomed-IdiSNA), Universidad Pública De Navarra (UPNA), IdiSNA (Navarra Institute for Health Research), C/Irunlarrea, 3 Pamplona, Navarra 31008, Spain Supplemental data for this article can be accessed here.…”

Section: Introductionmentioning

confidence: 99%

Early epigenetic changes of Alzheimer’s disease in the human hippocampus

et al. 2020

View full text Add to dashboard Cite

CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment

Brisson

Brodeur

Létourneau-Guillon

et al. 2020

A&D Transl Res & Clin Interv

View full text Add to dashboard Cite

Since 1989, four Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia (CCCDTDs) have provided evidence-based dementia diagnostic and treatment guidelines for Canadian clinicians and researchers. We present the results from the Neuroimaging and Fluid Biomarkers Group of the 5th CCCDTD (CCCDTD5), which addressed topics chosen by the steering committee to reflect advances in the field and build on our previous guidelines. Recommendations on Imaging and Fluid Biomarker Use from this Conference cover a series of different fields. Prior structural imaging recommendations for both computerized tomography (CT) and magnetic resonance imaging (MRI) remain largely unchanged, but MRI is now more central to the evaluation than before, with suggested sequences described here. The use of visual rating scales for both atrophy and white matter anomalies is now included in our recommendations. Molecular imaging with [ 18 F]-fluorodeoxyglucose ([18F]-FDG) Positron Emisson Tomography (PET) or [ 99m Tc]hexamethylpropyleneamine oxime/ethylene cysteinate dimer ([ 99m Tc]-HMPAO/ECD) Single Photon Emission Tomography (SPECT), should now decidedly favor PET. The value of [ 18 F]-FDG PET in the assessment of neurodegenerative conditions has been established with greater certainty since the previous conference, and it has now been recognized as a useful biomarker to establish the presence of neurodegeneration by a number of professional organizations around the world. Furthermore, the role of amyloid PET has been clarified and our recommendations follow those from other groups in multiple countries. SPECT with [ 123 I]-ioflupane (DaTscan TM ) is now included as a useful study in differentiating Alzheimer's disease (AD) from Lewy body disease. Finally, liquid biomarkers are in a rapid phase of development and, could lead to a revolution in the assessment AD and other neurodegenerative conditions at a reasonable cost.We hope these guidelines will be useful for clinicians, researchers, policy makers, and the lay public, to inform a current and evidence-based approach to the use of neuroimaging and liquid biomarkers in clinical dementia evaluation and management.

show abstract

Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: consensus proposal from the SEMNIM and SEN

Cited by 7 publications

References 95 publications

Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria

Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria

Early epigenetic changes of Alzheimer’s disease in the human hippocampus

CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment

Contact Info

Product

Resources

About